

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary) Sheet 2 of 4	<b>Application Number</b>	10/540,447
	<b>Filing Date</b>	06/22/2005
	<b>First Named Inventor</b>	Frans Eduard Janssens
	<b>Group Art Unit</b>	1624
	<b>Examiner Name</b>	E. Bernhardt
	<b>Attorney Docket Number</b>	JAB1731USPCT1

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		Aguiar et al., <i>Physiol. &amp; Behav.</i> 60:1183-1186 (1996)	
		Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC), <i>Annals of Oncol.</i> 9: 811-819 (1998)	
		Ballard et al., Inhibition of shock-induced foot tapping behaviour in the gerbil by a tachykinin NK1 receptor antagonist, <i>European Journal of Pharmacology</i> (2001), 412(3), pgs. 255-264	
		Bertrand et al., <i>Trends Pharmacol. Sci.</i> 17:255-259 (1996)	
		Brodin et al., <i>Neuropeptides</i> 26:253-260 (1994)	
		Campos et al., <i>J. Clin. Oncol.</i> 19:1759-1767 (2001)	
		Cocquyt et al., <i>Eur. J. Cancer</i> 37:835-842 (2001)	
		Culman et al., <i>Can. J. Physiol. Pharmacol.</i> 73:885-891 (1995)	
		De Mulder et al., <i>Annals of Internal Medicine</i> , 113:834-840 (1990)	
		Duffy, R. A., Expert Opin. Emerg. Drugs (2004), 9 (1), pgs. 9-21	
		Elliott, P. J., <i>Exp. Brain. Res.</i> 73:354-356 (1988)	
		Giardina, G. et al., <i>Exp. Opin. Ther. Patents</i> , 10(6): 939-960 (2000)	
		Hesketh et al., <i>Clin. Oncol.</i> 17:338-343 (1999)	
		Hesketh et al., <i>J. Clin. Oncol.</i> 15:103-109 (1997)	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary) Sheet 3 of 4	<b>Application Number</b>	10/540,447
	<b>Filing Date</b>	06/22/2005
	<b>First Named Inventor</b>	Frans Eduard Janssens
	<b>Group Art Unit</b>	1624
	<b>Examiner Name</b>	E. Bernhardt
	<b>Attorney Docket Number</b>	JAB1731USPCT1

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		Kramer <i>et al.</i> , <i>Science</i> 281:1640-1645 (1998)	
		Krase <i>et al.</i> , <i>Behav. Brain. Res.</i> 63:81-88 (1994)	
		Kris <i>et al.</i> , <i>J. Clin. Oncol.</i> 3:1379-1384 (1985)	
		Lejeune <i>et al.</i> , The selective neurokinin (NK) <sub>1</sub> antagonist, GR205,171, stereospecifically enhances mesocortical dopaminergic transmission in the rat: a combined dialysis and electrophysiological study, <i>Brain Research</i> (2002), 935, pgs. 134-139	
		Longmore <i>et al.</i> , <i>DN&amp;P</i> 8(1):5-23 (1995)	
		Lundberg, J., <i>Can. J. Physiol. Pharmacol.</i> 73:908-914 (1995)	
		Maggi and Schwartz, <i>Trends Pharmacol. Sci.</i> 18: 351-355 (1997)	
		Maggi, C. A., <i>Gen. Pharmacol.</i> 26:911-944 (1995)	
		Mattson <i>et al.</i> , <i>J. Org. Chem.</i> , 1990, 55, 2552-2554	
		Megens <i>et al.</i> , <i>J. Pharmacol. Exp. Ther.</i> 302:696-709 (2002)	
		Meltzer <i>et al.</i> , Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder, <i>The American Journal of Psychiatry</i> (2004), 161(6), pgs. 975-984	
		Navari <i>et al.</i> , <i>N. Engl. J. Med.</i> 340:190-195 (1999)	
		Naylor <i>et al.</i> , <i>Cancer. Surv.</i> 21:117-135 (1996)	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary) <b>Sheet 4 of 4</b>	<b>Application Number</b>	10/540,447
	<b>Filing Date</b>	06/22/2005
	<b>First Named Inventor</b>	Frans Eduard Janssens
	<b>Group Art Unit</b>	1624
	<b>Examiner Name</b>	E. Bernhardt
	<b>Attorney Docket Number</b>	JAB1731USPCT1

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		Okano et al., <i>J. Pharmacol. Exp. Ther.</i> 298:559-564 (2001)	
		Piedimonte et al., <i>J. Pharmacol. Exp. Ther.</i> 266:270-273 (1993)	
		Regoli et al., <i>Pharmacol. Rev.</i> 46(4):551-599 (1994)	
		Rein et al., Symposia, S.01. New treatment strategies in schizophrenia, S.01.01 Antipsychotic effect of four different compounds - results of the metatrial, European Neuropsychopharmacology Volume 13, Supplement 4, October 2003, Page S95	
		Rudd et al., <i>Neuropharmacology</i> 33:1607-1608 (1994)	
		Rudd et al., <i>Br. J. Pharmacol.</i> 119:931-936 (1996)	
		Rupniak et al., <i>Trends Pharmacol. Sci.</i> 20:485-490 (1999)	
		Sam et al., <i>Eur. J. Pharmacol.</i> 417:231-237 (2001)	
		Shirayama et al., <i>Brain. Res.</i> 739:70-78 (1996)	
		Stella, V. J. et al., "Prodrugs", <i>Drug Delivery Systems</i> , 1985, pp. 112-176	
		Stella et al., <i>Drugs</i> , 29, pp. 455-473 (1985)	
		Tattersall et al., <i>Neuropharmacology</i> 35:1121-1129 (1996)	
		Tattersall et al., <i>Neuropharmacology</i> 39:652-663 (2000)	
		Teixeira et al., <i>Eur. J. Pharmacol.</i> 311:7-14 (1996)	
		Tonini et al., <i>Gastroenterol.</i> 120:938-945 (2001)	
		Watson et al., <i>Br. J. Pharmacol.</i> 115:84-94 (1995)	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.